MONTREAL, Nov. 4, 2004 (PRIMEZONE) -- Viropro, Inc. (OTCBB:VPRO) announced today that it has created a new subsidiary, Viropro Pharma, that will focus on the marketing and distribution of products and advanced technologies in the lucrative field of Life Sciences.
Specializing in Generic Biopharmaceuticals, OTC Pharmaceuticals and Diagnostics, Viropro Pharma has identified particular interest in South America and Asia where it is already developing partnerships.
As part of its strategy, Viropro Pharma will place immediate emphasis on business development, the establishment of technology transfer agreements and the creation of long-term relationships with partners, distributors and suppliers on each target market.
Viropro Pharma will soon be appointing a scientific committee comprising internationally recognized subject matter experts to provide product and technical guidance as well as support to anticipated technical transfer initiatives.
According to Mr. Serge Beausoleil, who was recently appointed President of Viropro Canada, Inc. "The structure and tools are already in place for Viropro Pharma to position itself strategically and extremely competitively in international markets where there is clear opportunity for return over the short term." He added, "We also have strong relationships in markets where we know how to deal with unique legislations and procedures. It is a great challenge with terrific upside potential."
About Viropro, Inc.
Viropro, Inc. (OTCBB:VPRO) is seeking to establish a growth portfolio in Life Sciences markets through strategic alliances and revenue-producing acquisitions with the potential for continued shareholder value.
Viropro, Inc's Safe Harbor Statement
Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward looking statements". Forward looking statements in this release may be identified through the use of such words as "expects", "anticipates", "estimates", "believes", or statements indicating certain actions "may", "could", or "might" occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company's ability to market its products and services in a competitive environment as well as other factors.